Ask AI
ProCE Banner Activity

Research Focus in KRAS-Mutated NSCLC

Slideset

Download these slides to explore an expert review of the current role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including ongoing research and strategies to overcome barriers limiting current standards of care, such as emerging combination approaches and next-generation KRAS G12C inhibitors.

Released: April 30, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Genentech, a member of the Roche Group and Lilly.

Genentech, a member of the Roche Group

Lilly

Target Audience

This educational activity is intended for oncologists and other healthcare professionals who care for patients with non-small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with NSCLC who may be eligible for treatment with next-generation KRAS G12C–targeted therapies when they become available

  • Consider how next-generation KRAS G12C–targeted agents in late-phase clinical trials might be integrated into real-world clinical practice for patients with NSCLC

  • Discuss with colleagues and patients ongoing advances in targeting KRAS G12C for solid tumors